Aromatase: Contributions to physiology and disease in women and men

Physiology

Volumn 31, Issue 4, 2016, Pages 258-269

  Blakemore, Jennifer ^a   Naftolin, Fredrick ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; ESTROGEN;

ANIMAL; BRAIN; DISEASES; ENZYMOLOGY; FEMALE; GENETICS; HOMEOSTASIS; HUMAN; HUMAN DEVELOPMENT; IMMUNOLOGY; MALE; PHYSIOLOGY;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BRAIN; DISEASE; ESTROGENS; FEMALE; HOMEOSTASIS; HUMAN DEVELOPMENT; HUMANS; MALE;

EID: 84983805437     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00054.2015     Document Type: Review

References (169)

1. Agarwal SK, Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. Biomed Res (Tokyo) 2015: 878517, 2015.
2. Akhtar M, Njar VC, Wright JN. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. Steroid Biochem Mol Biol 44: 375-387, 1993.
3. Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquie M, Gauthier BR, Nef S, Stefani E, Nadal A. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLos One 3: E2069, 2008.
4. Alvarez-de-la-Rosa M, Silva I, Nilsen J, Pérez MM, García-Segura LM, Avila J, Naftolin F. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer’s disease. Ann NY Acad Sci 1052: 210-224, 2005.
5. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J Natl Cancer Inst 103: 1299-1309, 2011.
6. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9: 192-194, 2007.
7. Astle S, Slater DM, Thornton S. The involvement in the onset of human labour. Eur J Obstet Gynecol Reprod Biol 108:177-181, 2003.
8. Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast 22: 121-129, 2013.
9. Balthazart J. Steroid control and sexual differentiation of brain aromatase. J Steroid Biochem 61: 323-339, 1997.
10. Balthazart GF, Ball J. New insights into the regulation and function of brain estrogen synthase (aromatase). Trends Neurosci 21: 243-248, 1998.
11. Bechmann I, Goldmann J, Kovac AD, Kwidzinski E, Simburger E, Naftolin F, Dirnagl U, Nitsch R, Priller J. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia. FASEB J 19: 647-659, 2005.
12. Bell JR, Bernasochi GB, Varma U, Raaijmaerks AJA, Delbidge LMD. Sex and sex hormones in cardiac stress: Mechanistic insights. J Steroid Biochem 137: 124-135, 2013.
13. Berstein LM, Santner SJ, Brodie AM, Koos RD, Naftolin F, Santen RJ. Pseudoaromatase in circulating lymphocytes. J Steroid Biochem 44: 647-649, 1993.
14. Beyer C, Moralí G, Naftolin F, Larsson K, Pérez-palacios G. Effect of some antiestrogens and aromatase inhibitors on androgen induced sexual behavior in castrated male rats. Horm Behav 7: 353-363, 1976.
15. Bjornstrom M, Sjoberg L. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19: 833-842, 2005.
16. Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR. Extended adjuvant endocrine therapy in hormonereceptor positive early breast cancer: Current and future evidence. Cancer Treat Rev 41: 271-276, 2015.
17. Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss G, Limacher MC, Liu H, Mason E, Oberman A, O’Sullivan MJ, Phillips LS, Prineas RJ, Tinker L. The effect of conjugated equine oestrogen on diabetes incidence: The Women’s Health Initiative randomised trial. Diabetologia 49: 459-468, 2006.
18. Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, Liu FS, Fujino T, Barrett JC, McLachlan JA. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer 77: 507-513, 1996.
19. Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocytemediated, antibody-dependent cellular cytotoxicity. Am J Surg 190: 570-571, 2005.
20. Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol 27: 53-63, 2009.
21. Bulun SE, Utsonomiya H, Lin Z, Yin P, Cheng YH, Pavone ME, Tokunaga H, Trukhacheva E, Attar E, Gurates B, Milad MP, Confino E, Su E, Reierstad S, Xue Q. Steroidogenic factor-1, endometriosis. Mol Cell Endocrinol 300: 104-108, 2009.
22. Bulun SE. Aromatase and estrogen receptor alpha deficiency. Fertil Steril 101: 323-329, 2014.
23. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol 5:1-9, 2015.
24. Canick JA, Ryan KJ. Cytochrome P-450 and the aromatization of 16alpha-hydroxytestosterone and androstenedione by human placental microsomes. Mol Cell Endocrinol 6: 105-115, 1976.
25. Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR. Role of oestrogen in male sexual behavior: Insights from the natural model of aromatase deficiency. Clin Endocrinol 51: 517-524, 1999.
26. Cavalieri E1, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers:implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766:63-78, 2006.
27. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocrinology 23: 665-686, 2002.
28. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskin MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation effects on cognition in older men. Neurology 64: 290-296, 2005.
29. Chlebowski RT, Aragaki AK, Anderson GL. Menopausal hormone therapy influence on breast cancer outcomes in the Women’s Health Initiative. J Natl Compr Canc Netw 13: 917-924, 2015.
30. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNFinduced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest 93: 17-25, 1994.
31. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy:its origin, current status, and future. Menopause 20: 342-353, 2013.
32. Cohen PG. Obesity in men: The hypogonadolestrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 70: 358-360, 2008.
33. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 78: 1287-1292, 1994.
34. Csapo AI, Pinto-Dantas CA. The effect of progesterone on the human uterus. Proc Natl Acad Sci USA 54: 1069-1076, 1965.
35. Curatola AM, Huang K, Naftolin F. Dehydroepiandrosterone (DHEA) inhibition of monocyte binding by vascular endothelium is associated with sialylation of neural cell adhesion molecule. Reprod Sci 19: 86-91, 2012.
36. Deladoey J, Fluck C, Bex M, Yoshimura N, Harada N, Mullis PE. Aromatase deficiency caused by a novel P450arom gene mutation: Impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 84: 4050-4054, 1999.
37. Dey P1, Barros RP, Warner M, Ström A, Gustafsson JÅ. Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS. J Mol Endocrinol 51: 61-74, 2013.
38. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisenleder D, Krawetz SA, Barnhart K, Trussell JC, Ohl D, Jin Y, Santoro N, Eisenberg E, Zhang H; NICHD. Reproductive Medicine Network. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med 373: 1230-1240, 2015.
39. Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6: 21-28, 1999.
40. Dorrington JH, Armstrong DT. Follicle-stimulating hormone stimulates estradiol-17beta synthesis in cultured sertoli cells. Proc Natl Acad Sci USA 72: 2677-2681, 1975.
41. Drummond AE. The role of steroids in follicular growth. Reprod Biol Endocrinol 4: 450, 2006.
42. Easterling WK, Simmer HH, Dignam WJ, Frankland MV, Naftolin F. Neutral C19-steroids and steroid sulfates in human pregnancy 2. Dehydroepiandrosterone sulfate, 16alpha-hydroxydehydroepiandrosterone, and 16alpha-hydroxydehydroepiandrosterone sulfate in maternal and fetal blood of pregnancies with anencephalic and normal fetuses. Steroids 8: 157-178, 1992.
43. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87: 6-12, 1996.
44. Fahraeus L. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. Obstet Gynecol 72: 18-22, 1988.
45. Falahati-Nini A, Riggs BL, Atkinson EJ, O’fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone and resorption and formation in normal elderly men. J Clin Invest 106: 1553-1560, 2000.
46. Feuilan P, Merke D, Leschek EW, Cutler GB. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 6: 303-306, 1999.
47. Fishman J. Biochemical mechanism of aromatization. Cancer Res 42, Suppl 8: 3277-3280, 1982.
48. Franik S, Kremer JA, Nelen WL, Farquhar C, Marjoribanks J. Aromatase inhibitors for subfertile women with polycystic ovary syndrome: Summary of a Cochrane review. Fertil Steril 103: 353-355, 2015.
49. Frank GR. Role of estrogen and androgen in pubertal skeletal physiology. Pediatr Blood Cancer 41: 217-221, 2003.
50. Gascon E, Vutskits L, Kiss JZ. Polysialic acid-neural cell adhesion molecule in brain plasticity: From synapses to integration of new neurons. Brain Res Rev 56: 101-118, 2007.
51. Ge Q, Tan Q, Tseng H, Naftolin F. Developments of low-dose reproductive hormone therapies in China. Gynecol Endocrinol 22: 636-645, 2006.
52. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89: 5898-5907, 2004.
53. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of hormone therapy on cognition and mood in recently postmenopausal women: Findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med 12: E1001833, 2015.
54. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29: 677-696, 2008.
55. Greenblatt RB, Colle ML, Mahesh VB. Ovarian and adrenal steroid production in the postmenopausal woman. Obstet Gynecol 47: 383-387, 1976.
56. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 346: 340-352, 2002.
57. Guner OF, Bowen JP. Pharmacophore modeling for ADME. Curr Top Med Chem 13: 1327-1342, 2013.
58. Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The Women’s Health Initiative trial and related studies: 10 years later: A clinician’s view. J Steroid Biochem 42: 4-11, 2014.
59. Haluska GJ, Wells TR, Hirst JJ, Brenner RM, Sadowsky DW, Novy MJ. Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques:evidence for functional progesterone withdrawal at parturition. J Soc Gynecol Investig 9: 125-136, 2002.
60. Hammond GL. Diverse roles for sex hormonebinding globulin reproduction. Biol Reprod 85:431-441, 2011.
61. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson J. Estrogen receptors:How do they signal and what are their targets. Physiol Rev 87: 905-931, 2007.
62. Hiltuenen M, Iovenen S, Soininen H. Aromatase enzyme and Alzheimer’s disease. Minerva Endocrinol 31: 61-73, 2006.
63. Hodis HN, St John JA, Xiang M, Cushman M, Lobo RA, Mack WJ. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol 101: 1131-1133, 2009.
64. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 374: 1221-1231, 2016.
65. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncol Lett 9: 1495-1501, 2015.
66. Huszar G, Naftolin F. The myometrium and uterine cervix in normal and preterm labor. N Engl J Med 311: 571-581, 1984.
67. Hutton B, Yazdi F, Bordeleau L, Morgan S, Cameron C, Kanji S, Fergusson D, Tricco A, Straus S, Skidmore B, Hersi M, Pratt M, Mazzarello S, Brouwers M, Moher D, Clemons M. Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: Protocol for a systematic review incorporating network meta-analyses. Syst Rev 4: 1-7, 2015.
68. Hyder GM, Stancel SM. Regulation of angiogenci growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 13:806-811, 1999.
69. Ingle JN. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. Breast 22, Suppl 2: S180-S183, 2013.
70. Johnston SL, Farrell SA, Bouchard C, Beckerson LA, Corneau M, Lefebvre G, Papaioannou A. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 5: 503-515, 2004.
71. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK. Impaired endothelial function in young women with premature ovarian failure: Normalization with hormone therapy. J Clin Endocrinol Metab 89: 3907-3913, 2004.
72. Keefe DL. Sex hormones and neural mechanisms. Arch Sex Behav 31: 401-403, 2002.
73. Khosla S, Melton LJ, Atkinson EJ, O’fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen 1. J Clin Endocrinol Metab 83: 2266-2274, 1998.
74. Laughlin TJ, Sejnowski SB. Communication in neuronal networks. Science 301: 1870-1874, 2003.
75. Lavasani S, Chlebowski RT, Prentice RL, Kato I, Wactawski-Wende J, Johnson KC, Young A, Rodabough R, Hubbell FA, Mahinbakht A, Simon MS. Estrogen and colorectal cancer incidence and mortality. Cancer 121: 3261-3271, 2015.
76. Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S. Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: A prospective non-randomized study. Eur J Obstet Gynecol Reprod Biol 181: 157-162, 2014.
77. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit? Breast Cancer Res 11: 206-218, 2009.
78. Libby P. Current concepts of the pathogenesis of the acute coronary syndroms. Circulation 104:365-372, 2001.
79. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: Players and layers. Circ Res 116: 307-311, 2015.
80. Liu R, Yang S, Perez E, Yi KD, Wu SS, Eberst K, Prokai L, Prokai-Tatrai K, Cai ZY, Covey DF, Day AL, Simpkins JW. Neuroprotective effects of a novel non-receptor binding estrogen analogue:in vitro and in vivo analysis. Stroke 33: 2485-2491, 2002.
81. Lobo RA. Where are we 10 years after the Women’s Health Initiative? J Clin Endocrinol Metab 98: 1771-1780, 2013.
82. Longcope C, Baker R, Johnston CC. Androgen and estrogen metabolism: Relationship to obesity. Metabolism 35: 235-237, 1986.
83. MacLusky NJ, Naftolin F. Sexual differentiation of the central nervous system. Science 211:1294-1302, 1981.
84. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML. Estrogen therapy and coronaryartery calcification. N Engl J Med 256: 2591-2602, 2007.
85. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 93: 832-831, 2008.
86. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34: 309-338, 2013.
87. McCullough LD, Blizzard K, Simpson ER, Oz OK, Hurn PD. Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. J Neurosci 23: 8701-8705, 2003.
88. McNatty KP, Makris A, Degrazia C, Rapin O, Ryan KJ. The production of progesterone, androgens, and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab 49: 687-699, 1979.
89. Mesiano M, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: Do they hold the key to birth timing? Reprod Sci 18:6-19, 2011.
90. Miller VM, Lahr BD, Bailey KR, Heit JA, Harman SM, Jayachandran M. Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. Platelets 9: 1-11, 2015.
91. Miller WR, Santen R (editors). Aromatase Inhibition and Breast Cancer. New York: Marcel Dekker, 2001.
92. Mor G, Amir-Zaltsman Y, Barnard G, Ben-Hur H, Kohen F. Evidence for the expression of estrogen receptors in monocytes. Endocrine 1: 387-395, 1993.
93. Mor G, Nilsen J, Horvath T, Bechmann I, Brown S, Garcia-Segura LM, Naftolin F. Estrogen and microglia:a regulatory system that affects the brain. J Neurobiol 40: 484-496, 1999.
94. Mor G, Sapi E, Abrahams VM, Rutherford T, Song J, Hao XY, Muzaffar S, Kohen F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 170: 114-122, 2003.
95. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689-3698, 1995.
96. Murata T, Narita K, Honda K, Matsukawa S, Higuchi T. Differential regulation of estrogen receptor alpha and beta mRNAs in the rat uterus during pregnancy and labor: Possible involvement of estrogen receptors in oxytocin receptor regulation. Endocrine 50: 579-587, 2003.
97. Naftolin F. Brain aromatization of androgens. J Reprod Med 39: 257-261, 1994.
98. Naftolin F, Horvath TL, Jakab RL, Leranth C, Harada N, Balthazart J. Aromatase immunoreactivity in axon terminals of the vertebrate brain: An immunocytochemical study on qual, rat, monkey and human tissues. Neuroendocrinology 63:149-155, 1996.
99. Naftolin F, Judd HL. Testicular Feminization in Obstetrics and Gynecology. Annual Volume 2, edited by Wynn R. New York: Appleton-Century Crofts, 197325-53.
100. Naftolin F, Judd HL, Yen SS. Pulsatile patterns of gonadotropins and testosterone in man: The effects of clomiphene, with and without testosterone added. J Clin Endocrinol Metab 36: 285-288, 1973.
101. Naftolin F, Ryan KJ, Davies IJ, Reddy VV, Flores F, Petro Z, Kuhn M, White RJ, Takaoka Y, Wolin L. The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31: 295-319, 1975.
102. Naftolin F, Ryan KJ, Petro Z. Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats. Endocrinology 90:295-298, 1971.
103. Naftolin F, Schneider HPG, Sturdee DW, Birkhauser M, Brincat MP, Gambacciani M, Genazzini AR, Limpaphayom KK, O’Neill S, Palacios S, Pines A, Siseles N, Tan D, Burger HG. Guidelines for hormone treatment of women in the menopausal transition and beyond Position statement by the executive committee of the International Menopause Society (revised October 15, 2004). Climacteric 7: 333-337, 2004.
104. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 45: S116-S124, 2001.
105. Nilsen J, Brinton RD. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord 3: 297-313, 2004.
106. Nilsen J, Mor G, Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 43: 64-78, 2000.
107. Osawa Y, Higashiyama T, Shimizu Y, Yarborough C. Multiple functions of aromatase and the active site structure; aromatase is the placental estrogen 2-hydroxylase. J Steroid Biochem 44: 469-480, 1993.
108. Osawa Y, Higashiyama T, Toma Y, Yarborough C. Diverse function of aromatase and the N-terminal sequence deleted form. J Steroid Biochem 61: 117-126, 1997.
109. Park H, Pagan L, Tan O, Fadiel A, Demir N, Huang K, Mittal K, Naftolin F. Estradiol regulates expression of polysialated neural cell adhesion molecule by human vascular endothelial cells. Reprod Sci 17: 1090-1098, 2010.
110. Patry G, Jarvi K, Grober ED, Lo KC. Use of the aromatase inhibitor letrozole to treat male infertility. Fertil Steril 92: E1-e2, 2009.
111. Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril 98:1370-1379, 2012.
112. Perez-Lopez FR, Chedraui P, Gilbert JJ, Perez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions:facing the post-Women’s health inititiave era. Fertil Steril 92: 1171-1186, 2009.
113. 2+ channel blockade. Br J Pharmacol 149: 233-242, 2006.
114. Pinto RM, Fisch L, Schwarcz Rl Montuori E. Action of estradiol 17-beta upon uterine contractility and the milk-ejecting effect in the pregnant woman. Am J Obstet Gynecol 90: 99-107, 1964.
115. Pragnell M, Snay KJ, Trimmer JS, MacLusky NJ, Naftolin F, Kaczmarek LK, Boyle MB. Estrogen induction of a small, putative potassium channel mRNA in rat uterus. Neuron 4: 807-812, 1990.
116. Raman Schlegal PN JD. Aromatase inhibitors for male infertility. J Urol 167: 624-629, 2002.
117. Roberts ES, Vaz AD, Coon MJ. Catalysis by cytochrome P-450 of an oxidative reaction in xenobiotic aldehyde metabolism: Deformylation with olefin formation. Proc Natl Acad Sci USA 88:8963-8966, 1991.
118. Rocha-Cadman X1, Massie MJ, Du Hamel K. Aromatase inhibitors and mood disturbances. Palliat Support Care 10: 225-227, 2012.
119. Root-Bernstein R, Podufaly A, Dillon PF. Estradiol binds to insulin and insulin receptor decreasing insulin binding in vitro. Front Endocrinol 5: 1-13, 2014.
120. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin:recent advances. Endocr Rev 11: 80-91, 1990.
121. Ross JJ, Howlett SE. Age ovariectomy abolish beneficial effects of female sex on rat ventricular myocytes exposed to simulated ischemia and reperfusion. PLos One 6: E38425, 2012.
122. Rossouw JE. Reconciling the divergent findings from clinical trials and observational studies of menopausal hormone therapy for prevention of coronary heart disease. Semin Reprod Med 32:426-432, 2014.
123. Ryan KJ. Estrogen formation by the human placenta:studies on the mechanism of steroid aromatization by mammalian tissue. Acta Endocrinol 35: 697-698, 1960.
124. Ryan KJ, Hopper BR. Placental biosynthesis and metabolism of steroid hormones in primates. Contrib Primatol 3: 258-283, 1974.
125. Ryan KJ, Smith OW. Biogenesis of steroid hormones in the human ovary. Recent Prog Horm Res 21: 367-409, 1965.
126. Saito Y, Sakamoto H, MacLusky NJ, Naftolin F. Gap junctions and myometrial steroid hormone receptors in pregnant and postpartum rats: A possible cellular bases for progesterone withdrawal hypothesis. Am J Obstet Gynecol 151:805-812, 1985.
127. Saldanha CJ, Duncan KA, Walters BJ. Neurprotective actions of brain aromatase. Front Neuroendocrinol 30: 106-118, 2009.
128. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: Saga of an important biological mediator and therapeutic target. Endocr Rev 30: 343-375, 2009.
129. Santen RJ, Samojlik E, Lipton A,. Kinetic, hormonal and clinical studies with amnioglutethimide in breast cancer. Cancer 39: S2948-S2958, 1977.
130. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: An analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 103: 1583-1588, 2013.
131. Seruga B, Zadnik V, Kuhar CG, Marinko T, Cufer T, Zakotnik B, Zorman D, Ocana A, Amir E. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Invest 32: 99-104, 2014.
132. Shaywitz SE, Naftolin F, Zelterman D, Marchione KE, Holahan JM, Palter SF, Shaywtiz BA. Better oral reading and short-term memory in midlife, postmenopausal women taken estrogen. Menopause 10: 420-426, 2003.
133. Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Skudlarski P, Mencl WE, Constable RT, Naftolin F, Palter SF, Marchione KE, Katz L, Shankwiler DP, Fletcher JM, Lacadie C, Keltz M, Gore JC. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281: 1197-1202, 1999.
134. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 290: 2263-2270, 2003.
135. Sherwin BB. Estrogen and cognitive functioning in women: Lessons we have learned. Behav Neurosci 126: 123-127, 2012.
136. Shimizu Y, Yarborough C, Osawa Y. Competitive product inhibition of aromatase by natural estrogens. J Steroid Biochem 44: 651-656, 1993.
137. Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: Placental aromatase deficiency. J Clin Endocrinol Metab 72: 560-566, 1990.
138. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopuase: Long-term health consequences. Maturitas 65: 161-166, 2010.
139. Siiteri PK, Thompson EA. Studies of human placental aromatase. J Steroid Biochem 6: 317-322, 1975.
140. Silva I, Mor G, Naftolin F. Estrogen and the aging brain. Maturitas 38: 95-101, 2001.
141. Silva I, Naftolin F. Brain health and cognitive and mood disorders in ageing women. Best Pract Res Clin Obstet Gynaecol 27: 661-672, 2013.
142. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem 86: 225-230, 2003.
143. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendselon CR, Bulun SE. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342-355, 1994.
144. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase expression in health and disease. Recent Prog Horm Res 52: 185-213, 1997.
145. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001.
146. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442, 2003.
147. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98: 83-90, 1993.
148. Stocco C. Tissue physiology and pathology of aromatase. Steroids 77: 27-35, 2012.
149. Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care 9: 391-396, 2014.
150. Suhara K, Ohashi K, Takahashi K, Katagiri M. Aromatase and nonaromatizing 10-demethylase activity of adrenal cortex mitochondrial P450(11)beta. Arch Biochem Biophys 267: 31-37, 1988.
151. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Givercman A, Han TS, Kula K, Labrie F, Lean MEJ, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FCW, the Group EMAS. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95: 1810-1818, 2010.
152. Tan O, Harman SM, Naftolin F. What can we learn from design faults in the Women’s Health Initiative randomized clinical trial? Bull NYU Hosp Joint Dis 67: 226, 2009.
153. Tilson-Mallett N, Santner SJ, Feil PD, Santen RJ. Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 57: 1125-1128, 1983.
154. Toma Y, Higashiyama T, Yarborough C, Osawa Y. Diverse functions of aromatase: O-deethylation of 7-ethoxycoumarin. Endocrinology 137: 3791-3796, 1996.
155. Trösken ER, Scholz K, Lutz RW, Völkel W, Zarn JA, Lutz WK. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res 30: 387-394, 2004.
156. Tuncalp O, Edusa V, Fadiel A, Naftolin F. Understanding the Role of Aromatizable Androgens in Bone-Sparing in ISM Pisa Workshop on Bone, edited by Genazzani A. London: Taylor and Francis, 2005239-246.
157. Upala S, Sanguankeo A. Bariatric surgery and risk of postoperative endometrial cancer: A systematic review and meta-analysis. Surg Obes Relat Dis 11: 949-955, 2015.
158. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 25: 289-425, 2004.
159. Varfaj F, Zulkifli SN, Park HG, Challinor VL, De Voss JJ, Ortiz de Montellano PR. Carbon-carbon bond cleavage in activation of the prodrug nabumetone. Drug Metab Dispos 42: 828-838, 2014.
160. Wang X, Docanto MM, Sasano H,. Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer, Lo C., Simpson E.R, Brown KA. Prostaglandin E2 inhibits P43 in human breast adipose stromal cells: A novel mechanism for the regulation of aromatase in obesity and breast cancer. Cancer Res 75: 645-655, 2015.
161. Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. J Steroid Biochem 153: 35-44, 2015.
162. Wilson RA, Wilson TA. The fate of the nontreated postmenopausal woman: A plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc 11: 347-362, 1963.
163. Wooley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 14: 7680-7687, 1994.
164. Yanase T, Tanabe M, Nomiyama T. Sex hormones and metabolic function. Nihon Rinsho 73: 571-575, 2015.
165. Yen SSC, Tsai CC, Naftolin F, Vandenberg G, Ajabor L. Pulsatile patterns of gonadotropin release in subjcts with and without ovarian function. J Clin Endocrinol Metab 34: 671-675, 1972.
166. Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305: 315-322, 2003.
167. Yuan Y, Liao L, Tulis DA, Xu J. Steroid receptor coactivator-3 is required for inhabitation of neointima formation by estrogen. Circulation 105:2653-2659, 2002.
168. Zhao Z, Liu L, Li K, Li W, Zhao L, Zou H. Comparative study on individual aromatase inhibitors on cardiovascular safety profile: A network metaanalysis. Onco Targets Ther 8: 2721-2730, 2015.
169. Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C. Human models of aromatase deficiency. J Steroid Biochem 109: 212-218, 2008.